This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozyltrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab)
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • Tecentriq®▼ (atezolizumab) HCC
      • Tecentriq®▼ (atezolizumab) Lung Cancer
      • Tecentriq®▼ (atezolizumab) mTNBC
      • Tecentriq®▼ (atezolizumab) mUC
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    HEMLIBRA

     

     

    For routine prophylaxis of bleeding episodes in patients of all ages with congenital haemophilia A, classified as severe or with Factor VIII (FVIII) inhibitors1

    • HEMLIBRA®▼ (emicizumab)
    • Prescribing Info
    • Efficacy
      • Efficacy RCTs
      • Efficacy Non-RCTs
      • Study Designs
    • Safety
      • Pharmacovigilance
    • Dosing
    • PK and MOA
    • Publications
    • Surgery
      • Minor Surgery
      • Major Surgery
    • Lab Assays
      • Haemophilia A and Laboratory Tests
    • Horizons Meetings
    • More
      • Prescribing Info
      • Efficacy
      • Safety
      • Dosing
      • PK and MOA
      • Publications
      • Surgery
      • Lab Assays
      • Horizons Meetings

    You are here:

    1. Roche Medicines
    2. Rare Diseases
    3. HEMLIBRA®▼ (emicizumab)
    4. Safety
    HEMLIBRA delivers sustained protection with a consistent safety profile

    HEMLIBRA delivers sustained protection with a consistent safety profile2

    Roche/Chugai recognise the interest that the haemophilia community has around the long-term efficacy and safety of HEMLIBRA. We are committed to ensuring that healthcare professionals, patients and caregivers have the necessary information to make informed treatment decisions with HEMLIBRA.

    Please find below published information on the benefit–risk profile of HEMLIBRA, including long-term safety data, and educational materials on post-marketing safety reporting and pharmacovigilance. These are available for healthcare professionals to access on this website.

    Related links:

    • Efficacy
    • Pharmacokinetics and MOA
    • Laboratory assays
    • HEMLIBRA® Summary of Product Characteristics

    Pharmacovigilance: information on accurate and timely reporting of safety data.

    Links to publications discussing the efficacy and safety of HEMLIBRA in haemophilia A.

    For details on the concomitant use of HEMLIBRA with other medications please refer to the
    HEMLIBRA® Summary of Product Characteristics

    The following risk minimisation materials
    can be found at www.medicines.org.uk:

    • Guide for healthcare professionals
    • Guide for patients/caregivers
    • Patient alert card
    • Guide for laboratory professionals
    Safety Review. Read about the safety from HAVEN 1-4 and STASEY studies, severe adverse events (AEs) of interest and safety guidance

    For additional recent safety information, please refer to
    Publications

    Serious thrombotic events/thrombotic microangiopathy (TE/TMA) events were uncommon in the HAVEN studies1

    Serious TE/TMA events occurred in patients receiving HEMLIBRA prophylaxis when on average a cumulative amount of >100 u/kg daily of activated prothrombin complex concentrate (aPCC) for 24 hours or more was administered1

    Serious TE and TMA events occurred in 6.5% (2/31) and 9.7% (3/31) of patients, respectively, that received at least one dose of aPCC, while being treated with HEMLIBRA.1

    • Characteristics of TE/TMA events

      Four out of five patients improved within 1 month after HEMLIBRA interruption and aPCC discontinuation (n=373):3,4

      • Two patients restarted HEMLIBRA
      • One fatality due to rectal haemorrhage occurred, as the TMA event was resolving. Death was not attributed to HEMLIBRA5

      Characteristics of serious TE/TMA events in the HAVEN 1 study1,4,6

      Evidence of improvement was distinct from the usual clinical course observed in atypical haemolytic uremic syndrome and classic TMA events, such as thrombotic thrombocytopenic purpura.1

    • Summary of TE/TMA events

      Summary of TE/TMA events in all patients that had received HEMLIBRA up until 31 December 2019 (all events reported during and after clinical trials)7

      Summary of all TE/TMA events (all events reported during and after clinical trials, up until 31.12.19)

      *Events reported include off-label use of HEMLIBRA for patients with acquired haemophilia A (AHA). HEMLIBRA is only indicated in patients with congenital haemophilia A classified as severe or with Factor VIII inhibitors.

      All non-aPCC-associated TEs occurred in patients with known co-morbidities or pre-existing risk factors:7,8

      • Six cases of non-aPCC-associated myocardial infarction occurred in patients with known cardiovascular risk factors
      • Two TEs were identified in the long-term follow-up of:2,9
        • HAVEN 1, in a patient with non-serious device occlusion and a history of device-related thrombosis
        • HAVEN 3, in a patient >65 years, with undiagnosed coronary artery disease
      • In seven out of nine patients (two events occurred in one person) with non-device-related TEs, there was no reported change to HEMLIBRA prophylaxis as a result of the event

    HEMLIBRA was generally well tolerated1

    Summary of adverse drug reactions (ADRs) from pooled HAVEN clinical trials (n=373; phase III, median duration, 33 weeks)

    Untitled Document

    POOLED ANALYSIS

    System organ class (SOC)

    ADR

    Frequency

    Nervous system disorders

    Headache

    Very common (≥1/10)

    General disorders and administration site conditions

    Injection site reaction

    Very common

    Musculoskeletal and connective tissue disorders

    Arthralgia

    Very common

    General disorders and administration site conditions

    Pyrexia

    Common (≥1/100 to <1/10)

    Gastrointestinal disorders

    Diarrhoea

    Common

    Musculoskeletal and connective tissue disorders

    Myalgia

    Common

    Blood and lymphatic system disorders

    TMA event

    Uncommon (≥1/1,000 to <1/100)

    Skin and subcutaneous tissue disorders

    Skin necrosis

    Uncommon

    Vascular disorders

    Thrombophlebitis superficial

    Uncommon

    Vascular disorders (secondary SOC)

    Cavernous sinus thrombosis

    Uncommon

    Please refer to the SPC for the full list of ADRs.

    •  Three patients (0.8%) withdrew from treatment due to ADRs (TMA event, n=1; skin necrosis and superficial thrombophlebitis, n=1; headache, n=1)
    •  95% of injection site reactions resolved without treatment

    Safety considerations for patients receiving HEMLIBRA1

    Clinical trial experience with HEMLIBRA indicated that:

    • Concomitant use with FVIII and rFVIIa alone have not been associated with serious adverse events, including TE or TMA events
    • A drug interaction exists with HEMLIBRA and aPCC

    Avoid aPCC with HEMLIBRA, unless no other treatment options are available.

    For more details on the concomitant use of HEMLIBRA with other medications please refer to the
    HEMLIBRA® Summary of Product Characteristics

    The following risk minimisation materials
    can be found at www.medicines.org.uk:

    • Guide for healthcare professionals
    • Guide for patients/caregivers
    • Patient alert card
    • Guide for laboratory professionals

    HEMLIBRA increases a patient’s coagulation potential1

    If administering systemic haemostatic agents with HEMLIBRA:

    • Hypercoagulability is possible, based on preclinical experiments
    • Dose required to achieve haemostasis may be lower than when used without HEMLIBRA

    Considerations for concomitant use with: 

    • Factor VIII (FVIII)¹

      Clinical experience indicated that concomitant FVIII use has not been associated with serious AEs1

      Most breakthrough bleeds were treated with FVIII <50 u/kg/day for <24 hours (HAVEN 3)10

      Percentages based on 215 treatment events, in 64 patients. 

      *A treatment event started with the first FVIII treatment and included all infusions up to 36 hrs. Treatment events included administration of FVIII to treat a bleed and preventative doses given before a medical procedure or activity.

    • Bypassing agents (BPAs)¹

      Treatment with BPAs should be discontinued the day before initiating HEMLIBRA prophylaxis

      If BPAs are needed during HEMLIBRA prophylaxis:

      • Dose and duration will depend on the patient’s clinical condition, the location and extent of bleeding
      • Dose may be lower than that used without HEMLIBRA prophylaxis
      • BPA dosing guidance should be followed for at least 6 months, following discontinuation of HEMLIBRA prophylaxis

      Please refer to the SPC for further information about special warnings and precautions, guidance on concomitant use of HEMLIBRA with BPAs, and the full list of adverse events.

      Clinical experience indicated that concomitant rFVIIa use has not been associated with serious adverse events

      No TE/TMA events were observed in clinical trials, in patients receiving rFVIIa alone with HEMLIBRA.

    • Activated prothrombin complex concentrate (aPCC)¹

      Clinical experience has indicated that a drug interaction exists with HEMLIBRA and aPCC

      • Serious TE/TMA events were observed in patients receiving concomitant aPCC for treatment of a breakthrough bleed, in the HAVEN studies
      • Events were reported in patients receiving HEMLIBRA when a cumulative dose of aPCC, averaging >100 u/kg/day for ≥24 hours was administered

       

      Avoid aPCC with HEMLIBRA, unless no other treatment options are available

      • If aPCC is indicated, the total dose should not exceed 100 u/kg in the first 24 hours of treatment
        • Initial dose should not exceed 50 u/kg; additional doses should be administered under medical supervision, with laboratory monitoring recommended
        • Weigh the risk of TE/TMA events when considering aPCC >100 u/kg in the first 24 hours
        • If aPCC is administered with HEMLIBRA, monitor patients for TE/TMA events

    Long-term safety2

    Safety outcomes were consistent over time with HEMLIBRA prophylaxis, in the HAVEN 1–4 studies (median duration of treatment: 120 weeks; interquartile range 89–164).

    Untitled Document

    POOLED ANALYSIS (N=399)

    Total number of participants with ≥1 adverse event (AE), n (%)

    381 (95.5)

    Total number of patients, n (%)

    AE with fatal outcome

    1 (0.3)

    Serious AE

    93 (23.3)

    AE leading to withdrawal from treatment

    5 (1.3)

    Grade ≥3 AE

    87 (21.8)

    Treatment-related AE

    139 (34.8)

    Local injection site reaction

    111 (27.8)

    AEs of special interest

    Systemic hypersensitivity/anaphylactic/anaphylactoid reaction

    1 (0.3)*

    All TMA events

    3 (0.8)

    TMA events related to concomitant aPCC and HEMLIBRA

    3 (0.8)

    All TE

    4 (1.0)**

    TE related to concomitant aPCC and HEMLIBRA

    2 (0.5)

    The safety population only included those patients who received HEMLIBRA. One participant in HAVEN 1 discontinued prior to HEMLIBRA treatment and was excluded from the safety analyses.
    *Assessed using clinical criteria for diagnosing anaphylaxis (Sampson HA et al. J Allergy Clin Immunol 2006;117:391-7) and includes all participants that experienced indicative symptoms.
    **Of the two TEs not related to concomitant aPCC and HEMLIBRA, one TE was associated with device occlusion of a peripherally inserted central catheter and the other with a myocardial infarction.

    .

    ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As HEMLIBRA® is a biological medicine, healthcare professionals should report adverse reactions by brand and batch number.

    For full details please refer to the HEMLIBRA® Summary of Product Characteristics.

     

    AE, adverse event; ADR, adverse drug reaction; AHA, acquired haemophilia A; aPCC, activated prothrombin complex concentrate; BPA, bypassing agent; FVIII, Factor VIII; MOA, mechanism of action; rFVIIa, activated recombinant Factor VII; SOC, system organ class; TE, thrombotic events; TMA, thrombotic microangiopathy.

    References:

    1. HEMLIBRA SPC.
    2. Callaghan MU et al. ASH 2020:1800 [Poster Presentation].
    3. Oldenburg J et al. New Eng J Med 2017;377:809–18.
    4. Oldenburg J et al. New Eng J Med 2017;377:809–18 [Supplementary Appendix].
    5. Khoo L et al. Haemophilia 2020; DOI: 10.1111/hae.14110 (ePub ahead of print).
    6. Data on file. F. Hoffmann-La Roche. HEMI-2018-01.
    7. Lee L et al. EAHAD 2020 [Oral Presentation].
    8. Kruse-Jarres R & Hay CRM. N Eng J Med 2020;382:785.
    9. Callaghan MU et al. ASH 2020:1800 [Abstract].
    10. Mahlangu J et al. New Eng J Med 2018;379:811–22. [Supplementary Appendix].

    M-GB-00002370

    Date of preparation: December 2020

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.